Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rasagiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 13/20 | 1.00 |
| ▸ | MAOA | P21397 | 10/20 | 1.00 |
| ▸ | ACHE | P22303 | 3/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azilect SCHEMBL332967 | 1.00 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2827373 | 1.00 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL12787613 | 1.00 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL333333 | 1.00 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Azilect SCHEMBL29605291 | 1.00 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL828802 | 0.98 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2028892 | 0.98 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL5449858 | 0.98 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL316969 | 0.98 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2349557 | 0.98 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15612 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026106939-A1 | IMPROVING SYMPTOMS IN MID- TO LATE-STAGE PARKINSON'S DISEASE PATIENTS USING WITH DEEP BRAIN STIMULATION | VANDERBILT UNIVERSITY (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260131140-A1 | MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION | VANDERBILT UNIV (US) | 2026-05-14 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4701593-A1 | DIGITAL THERAPEUTICS | Remepy Health Ltd (IL) | 2026-03-04 | — | — | EP | claimed |
| EP-4687683-A1 | CONTROL OF ULTRASOUND PROCEDURES BY MONITORING MICROBUBBLE RESPONSE | Insightec Ltd. (IL) | 2026-02-11 | — | — | EP | claimed |
| WO-1996026720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOAMINE OXIDASE B INHIBITORS | R.P. SCHERER LIMITED (GB) | 1996-09-06 | — | — | WO | claimed |
| US-5532415-A | MONOAMINE OXIDASE INHIBITORS; PARKINSON'S DISEASE, NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1996-07-02 | — | — | US | claimed |
| US-5519061-A | MONOAMINE OXIDASE INHIBITORS, PARKINSON'S DISEASE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1996-05-21 | — | — | US | claimed |
| US-5457133-A | Treating Parkinson's disease, memory disorders, Alzheimer's disease, depression and hyperactive syndrome | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-10-10 | — | — | US | claimed |
| US-5453446-A | Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1995-09-26 | — | — | US | claimed |
| WO-1995011016-A1 | R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, COMPOSITIONS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-04-27 | — | — | WO | claimed |
| US-5387612-A | Administering title compound or salt; memory disorders | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-02-07 | — | — | US | claimed |
| EP-0436492-B1 | R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it | TEVA PHARMA (IL) | 1994-06-08 | — | — | EP | claimed |
| EP-0436492-A2 | R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it | Teva Pharmaceutical Industries Limited (IL) | 1991-07-10 | — | — | EP | claimed |
| CN-86102020-A | The preparation method of rhizoxin derivatives and in pharmaceutically application | — | 1986-10-01 | — | — | CN | claimed |